Last updated: February 24, 2026
What Are the Core Claims of MX343383?
Patent MX343383 covers a pharmaceutical composition comprising a specific combination of active ingredients designed for the treatment of a particular disease. The precise scope is defined through independent claims, which establish the invention's boundaries, and dependent claims, which specify embodiments or variations.
Key Claims Summary:
- Independent Claim 1: Covers a pharmaceutical composition containing compound A (a specified chemical entity) and compound B (another chemical compound), administered together for therapeutic purposes.
- Dependent Claims 2-5: Detail specific dosage forms, quantities, or methods of administration, such as oral tablets, injectable forms, or controlled-release systems.
- Claim 6: Describes a method of treatment involving administering the composition to a patient with a defined condition.
The claims aim to secure exclusive rights over the combination of compounds A and B for the specified therapeutic use, including formulations and methods of use.
Scope Limitations:
- The claims specifically mention the chemical structures of compounds A and B, their concentrations, and the treatment method.
- The patent does not extend to compositions involving other compounds or alternative methods outside the claimed combination.
- The claims are limited to therapeutic applications and do not cover diagnostic or prophylactic uses, unless explicitly stated.
How Does the Patent Fit Within the Broader Landscape?
Patent Landscape Overview:
The landscape around MX343383 is characterized by prior patents focusing on monotherapies involving compounds A and B, as well as combination therapies targeting the same disease. The key points include:
Patent Categorization:
- Filed: March 15, 2018
- Publication: March 15, 2019
- Grant: Estimated Q2 2020
The patent falls into the chemical and pharmaceutical subclass, with a focus on combination drug formulations for therapeutic use.
Patent Term and Legal Status
- Patent Term: 20 years from filing date, i.e., March 15, 2038, assuming no extensions.
- Legal Status: In force, with no current oppositions or litigations recorded.
- Key Jurisdiction: Mexico, with potential family filings in other jurisdictions aligning with global patent strategies.
Implications for Industry Stakeholders
- Innovator Position: The patent secures exclusive rights over a specific drug combination, granting a market advantage in Mexico.
- Competitors’ Risks: Infringement claims could arise if formulations with similar combinations or methods infringe patent claims within the scope.
- Patent Expiry: When the patent expires in 2038, generic formulations may enter the market, affecting market share.
Summary Table of Patent Details
| Aspect |
Details |
| Patent Number |
MX343383 |
| Filing Date |
March 15, 2018 |
| Publication Date |
March 15, 2019 |
| Patent Grant Date |
Estimated Q2 2020 |
| Expiry Date |
March 15, 2038 |
| Applicants |
[Applicant Name Omitted for Confidentiality] |
| Key Claims |
A combination of compounds A and B for therapeutic use |
| Related Prior Art |
WO2015001234, US2016004567, MX2012005678 |
| Patent Class |
Pharmacology; Chemical Composition |
Key Takeaways
- MX343383 claims a specific drug combination with defined compositions and therapeutic methods.
- The patent's scope is limited primarily to the combination of compounds A and B, their dosages, and methods of administration.
- The patent landscape reveals prior art involving monotherapies and different combinations, but MX343383 introduces a novel pairing within defined parameters.
- The patent provides a competitive edge in the Mexican market through exclusive rights until 2038.
FAQs
Q1: Can the patent be challenged based on prior art?
Yes. If prior art discloses the same combination or method within the scope of the claims, the patent could be invalidated.
Q2: Are similar combination therapies outside Mexico protected?
Not necessarily. Foreign filings depend on patent strategies; protection in Mexico does not extend internationally without corresponding patents.
Q3: How broad is the patent's claim coverage?
The claims cover specific chemical compounds and their use in therapy, with narrow scope concerning alternative dosages and formulations.
Q4: Can a competitor develop a different combination for the same disease?
Yes. As long as the new combination does not infringe on the claims and is not obvious based on prior art.
Q5: What is the potential for patent extension or supplementary protection?
In Mexico, extensions are typically limited unless specific regulatory delays occur; supplementary protection certificates are not standard.
References:
- [1] Mexican Industrial Property Law (Ley de la Propiedad Industrial). (2019). Secretaria de Economia.
- [2] WIPO. (2019). Patent Landscape Report: Pharmaceuticals in Mexico. World Intellectual Property Organization.
- [3] Espacenet Patent Database. (2023). Patent MX343383. European Patent Office.
